PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
|
|
|
- Homer York
- 5 years ago
- Views:
Transcription
1 PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Afatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP: MALE FEMALE SPECIAL REQUIREMENTS: (e.g. other language/other communication method) RESPONSIBLE HEALTH PROFESSIONAL: Name: NAME OF PROPOSED COURSE OF TREATMENT (include brief explanation if medical term not clear) Afatinib for the treatment of non-small cell lung cancer (NSCLC). Tablets are taken orally once a day, treatment is supplied every 28 days (one cycle). Treatment is continued until disease progression or unacceptable toxicity. WHERE THE TREATMENT WILL BE GIVEN: outpatient day unit/case inpatient other: STATEMENT OF HEALTH PROFESSIONAL (to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in the hospital/trust s consent policy) I have explained the procedure/treatment to the patient. In particular, I have explained: all relevant boxes THE INTENDED BENEFITS CURATIVE to give you the best possible chance of being cured. DISEASE CONTROL/PALLIATIVE the aim is not to cure but to control or shrink the disease. The aim is to improve both quality of life and survival. ADJUVANT therapy given after surgery to reduce the risk of the cancer coming back. NEO-ADJUVANT therapy given before surgery/radiotherapy to shrink the cancer, allow radical treatment and reduce the risk of the cancer coming back. Page 1 of 5
2 STATEMENT OF HEALTH PROFESSIONAL (continued) SIGNIFICANT, UNAVOIDABLE OR FREQUENTLY OCCURRING RISKS COMMON SIDE EFFECTS: More than 10 in every 100 (>10%) people have one or more of the side effects listed: Diarrhoea, skin changes (rash, dryness, itching, and acne-like rash), nail changes and infections, feeling sick (nausea) and being sick (vomiting), sore mouth and ulcers, loss of appetite, and nose bleeds. OCCASIONAL SIDE EFFECTS: Between 1 and 10 in every 100 (1-10%) people have one or more of these effects: Eye problems (red, sore or dry eyes), sore hands and feet (some people develop soreness, redness and peeling on the palms of the hands and soles of the feet), changes in the way the liver and kidneys work (usually temporary), inflammation of the bladder lining, taste changes, stomach pains and indigestion, muscle cramps, runny nose, high temperatures, and weight loss. OTHER RISKS: Changes in lung tissue that may cause a cough or breathlessness is a rare side effect. Let your doctor or nurse know straight away if you have a sudden cough, breathlessness or a high temperature. Severe eye pain and redness is a rare side effect. Tell your doctor or nurse straight away if you have this or watery eyes, blurred vision and sensitivity to light. You may need urgent treatment. Inflammation of the pancreas (pancreatitis) is a rare side effect. Cancer can increase your risk of developing a blood clot (thrombosis), and having treatment with anti-cancer medicines may increase this risk further. A blood clot may cause pain, redness and swelling in a leg, or breathlessness and chest pain - you must tell your doctor straight away if you have any of these symptoms. Some anti-cancer medicines can damage women s ovaries and men s sperm. This may lead to infertility in men and women and/or early menopause in women. Some anti-cancer medicines may damage the development of a baby in the womb. It is important not to become pregnant or father a child while you are having treatment and for at least 1 month afterwards. It is important to use effective contraception during and for at least 1 month after treatment. You can talk to your doctor or nurse about this. Very rarely complications of treatment with anticancer medicines can be life-threatening or even result in death. The risks are different for every individual. You can talk to your doctor or nurse about what this means for you. Page 2 of 5
3 STATEMENT OF HEALTH PROFESSIONAL (continued) ANY OTHER RISKS: I have discussed what the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, blood and any additional tests, follow-up appointments etc) and location. I have discussed the intended benefits and risks of any available alternative treatments (including no treatment) and any particular concerns of this patient. THE FOLLOWING LEAFLET HAS BEEN PROVIDED: Information leaflet for afatinib. 24 hour chemotherapy service contact details Other, please state: STATEMENT OF INTERPRETER (where appropriate) INTERPRETER BOOKING REFERENCE (if applicable): I have interpreted the information above to the patient to the best of my ability and in a way in which I believe s/he can understand. Page 3 of 5
4 STATEMENT OF PATIENT Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of the form which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask we are here to help you. You have the right to change your mind at any time, including after you have signed this form. I agree to the procedure and course of treatment described on this form. I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate training and experience. I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health. I have been told about additional procedures which may become necessary during my treatment. I have listed below any procedures which I do not wish to be carried out without further discussion: Patient s signature: A witness should sign below if the patient is unable to sign but has indicated his or her consent. Young people/children may also like a parent to sign here (see notes). Parent s/witness signature: COPY ACCEPTED BY PATIENT: YES / NO (please circle) CONFIRMATION OF CONSENT (health professional to complete when the patient attends for treatment, if the patient has signed the form in advance) On behalf of the team treating the patient, I have confirmed with the patient that s/he has no further questions and wishes the procedure to go ahead. IMPORTANT NOTES: (tick if applicable) See also advance decision to refuse treatment Patient has withdrawn consent (ask patient to sign /date here) FURTHER INFORMATION FOR PATIENTS CONTACT DETAILS (if patient wishes to discuss options later): Contact your hospital team if you have any questions about cancer and treatment. Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone , Monday to Friday, 9am to 5pm. Alternatively visit for more information. These forms have been produced by Guy s and St. Thomas NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT. The project is supported by Cancer Research UK. This does not mean you are taking part in a clinical trial. Page 4 of 5
5 GUIDANCE FOR HEALTH PROFESSIONALS (to be read in conjunction with the hospital s consent policy) WHAT A CONSENT FORM IS FOR This form documents the patient s agreement to go ahead with the investigation or treatment you have proposed. It is not a legal waiver if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way, however, should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient. THE LAW ON CONSENT See the Department of Health s Reference guide to consent for examination or treatment 2nd Edition for a comprehensive summary of the law on consent (also available at WHO CAN GIVE CONSENT Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has sufficient understanding and intelligence to enable him or her to understand fully what is proposed, then he or she will have capacity to give consent for himself or herself. Young people aged 16 and 17, and younger children with capacity, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent for himself or herself, someone with parental responsibility may do so on their behalf and a separate form is available for this purpose. Even where a child is able to give consent for himself or herself, you should always involve those with parental responsibility in the child s care, unless the child specifically asks you not to do so. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that the patient has given consent orally or non-verbally. WHEN NOT TO USE THIS FORM If the patient is 18 or over and lacks the capacity to give consent, you should use an alternative form (form for adults who lack the capacity to consent to investigation or treatment) instead of this form. A patient lacks capacity if they have an impairment of the mind or brain or disturbance affecting the way their mind or brain works and they cannot: understand information about the decision to be made retain that information in their mind use or weigh this information as a part of their decision making process, or communicate their decision (by talking, using sign language or any other means) You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy. INFORMATION Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about significant risks which would affect the judgement of a reasonable patient. Significant has not been legally defined, but the GMC requires doctors to tell patients about significant, unavoidable or frequently occurring risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient s notes. REFERENCES 1. Summary of Product Characteristics (SPCs) for individual drugs: 2. Cancer Research UK: about-cancer/cancers-in-general/treatment/cancer-drugs/ 3. Macmillan Cancer Support, Cancer Information: macmillan.org.uk/cancerinformation/cancertreatment/ Treatmenttypes/Chemotherapy/Chemotherapy.aspx 4. Guy s and St. Thomas NHS Foundation Trust, Chemotherapy consent forms. Page 5 of 5
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lomustine PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- platinum-based chemotherapy) HOSPITAL NAME/STAMP: PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- Chemotherapy) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Vinorelbine (oral) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Cisplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lenvatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Doxorubicin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX)
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX) Patient s surname/family name Patient s first names Date of birth Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION
Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM VISMODEGIB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM VISMODEGIB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St.
PATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title
Patient identifier/label: Page 1 of 5 GENERIC CONSENT FORM Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE. Patient s first names
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s
Oral Ibrutinib (single agent)
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IBRUTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IMATINIB. Patient s first names.
Patient identifier/label: Page 1 of 5 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
Patient identifier/label: Page 1 of 6. Patient s first names. Date of birth
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ENZALUTAMIDE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FMD. Patient s first names.
Patient identifier/label: Page 1 of 6 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB
Patient identifier/label: Page 1 of 6 FORM CHOP 21 + RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital
PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM WEEKLY RITUXIMAB. Patient s first names. Date of birth
Page 1 of 5 FORM WEEKLY RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DENOSUMAB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DENOSUMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas
Patient agreement to investigation, treatment or procedure
Appendix A: Consent Form 1 Consent form 1 Patient agreement to investigation, treatment or procedure Patient details (or pre-printed label) Patient s surname/family name... Patient s first names.. Date
Sentinel node biopsy. Patient Information to be retained by patient
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label Sentinel Node Biopsy What is a sentinel node biopsy? The lymphatic drainage from your
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 1) PATIENT AGREEMENT TO INVESTIGATION OR TREATMENT Patient Details or pre-printed label Patient s NHS Number or Hospital number
Cobimetinib (Cotellic ) ( koe-bi-me-ti-nib )
Cobimetinib (Cotellic ) ( koe-bi-me-ti-nib ) How drug is given: by mouth Purpose: to stop the growth of melanoma cancer cells How to take this drug 1. This drug can be taken with or without food. 2. Swallow
New Patient Registration Form NJR_NP_F100
New Patient Registration Form NJR_NP_F100 Patient Last Name First Name Middle Name Maiden Name Address (Street or Box) City State Zip Code Home Phone Number Cell Phone Number Work Phone Number E-Mail Patient
Methylprednisolone and Cyclophosphamide for lung fibrosis Information for patients
Methylprednisolone and Cyclophosphamide for lung fibrosis Information for patients This leaflet can be made available in other formats including large print, CD and Braille and in languages other than
University College London Hospitals (UCLH) Preventing venous thromboembolism (VTE)
University College London Hospitals (UCLH) Preventing venous thromboembolism (VTE) Information for adult inpatients and for patients due to be admitted If you need a large print, audio, braille, easy read
What is TB? Prevention is better than cure. You can get latent or active TB even if you have had a BCG vaccination
What is TB? Tuberculosis (TB) is an illness caused by bacteria. When someone with TB in their lungs coughs or sneezes, they send TB bacteria into the air. If you breathe in these bacteria, one of three
Having a Vena Cava Filter
Having a Vena Cava Filter Department of Radiology Information for Patients i Radiology Leaflet No. 30 Contents Page number Introduction 3 Referral and consent 3 Why do I need a vena cava filter inserted?
WELCOME TO THE UPMC LIVER CANCER CENTER PLEASE FILL OUT AND BRING WITH YOU TO YOUR APPOINTMENT
WELCOME TO THE UPMC LIVER CANCER CENTER PLEASE FILL OUT AND BRING WITH YOU TO YOUR APPOINTMENT You are scheduled to have an appointment at the UPMC Liver Cancer Center which is located in the UPMC Montefiore
WITHOUT YOUR WRITTEN CONSENT, WE CAN NOT SPEAK TO ANYONE REGARDING YOUR MEDICAL CARE due to privacy laws. You have the right to list anyone you
PATIENT REGISTRATION FORM PLEASE PRINT : Referring Physician: Primary Care: Patient s Name: Last First: M.I. Address: City: State: Zip: Home Phone: Cell: Work: Email: Preferred Contact Method Race: Ethnicity:
Treatment of non-muscle invasive bladder cancer with BCG and EMDA MMC
Treatment of non-muscle invasive bladder cancer with BCG and EMDA MMC This information sheet has been given to you to explain the combined use of BCG and EMDA MMC to treat your non-muscle invasive bladder
Emergency Care for Blood and Marrow Transplant Patients
PATIENT EDUCATION patienteducation.osumc.edu Emergency Care for Blood and Marrow Transplant Patients General Guidelines for Emergency Care Use these guidelines to know when and how to report any problems
Wirral Community NHS Trust Consent Form 4
Wirral Community NHS Trust Consent Form 4 Form for adults who are unable to Consent to investigation or treatment Patient details (or pre-printed label) Patient's surname/family name Patients first names
Etoposide (VePesid ) ( e-toe-poe-side )
Etoposide (VePesid ) ( e-toe-poe-side ) How drug is given: by mouth Purpose: to stop the growth of cancer cells in ovarian cancer, small cell lung cancer, Hodgkin disease, and other cancers How to take
Generator or box changes for your implantable device
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a generator? The generator (sometimes called the box ) is the battery that
C-GALL PATIENT INFORMATION LEAFLET
C-GALL PATIENT INFORMATION LEAFLET The purpose of this study is to compare keyhole gall bladder surgery (laparoscopic cholecystectomy) with watchful waiting in people who suffer from pain due to gallstones
Chemotherapy services at the Cancer Centre at Guy s
Chemotherapy services at the Cancer Centre at Guy s This leaflet aims to give you an overview of chemotherapy services at the Cancer Centre at Guy s. Chemotherapy services are delivered in two areas: Chemotherapy
Last Name: First Name: Advance Directive including Power of Attorney for Health Care
Patient Medical Record Number: Or Label Advance Directive including Power of Attorney for Health Care Overview This legal document meets the requirements for Wisconsin.* It lets you Name another person
Harvoni for the treatment of Hepatitis C
Harvoni for the treatment of Hepatitis C Department of Hepatology Digestive Diseases Centre Patient Information This leaflet is designed to give you important information about your new medicine. It is
Entrance Case History (Please write or print clearly)
Stony Brook Medical Park 2500 Nesconset Highway Suite 4-A Stony Brook, NY 11790 (631) 675-9000 Fax (631) 675-9002 www.naturalapproach.us Entrance Case History (Please write or print clearly) Today s Date
Patient copy. Periurethral bulking agent for stress urinary incontinence. Patient Information to be retained by patient
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label Who is this leaflet for? This leaflet provides information about having an injection
Preventing hospital-acquired blood clots
Preventing hospital-acquired blood clots Haematology Department Patient information leaflet This leaflet explains more about blood clots, which can form after illness and surgery. What are hospital-acquired
Last Name: First Name: Advance Directive. including Power of Attorney for Health Care
Overview Patient Medical Record Number: Or Label Advance Directive including Power of Attorney for Health Care This legal document meets the requirements for Wisconsin.* It lets you Name another person
Partial glossectomy. Your operation explained. Information for patients Head and Neck Centre
Partial glossectomy Your operation explained Information for patients Head and Neck Centre page 2 of 12 This leaflet provides information about the procedure known as partial glossectomy. It explains what
Instruction Sheet for Completing Health Care Power of Attorney/Living Will (Please discard instruction sheet after completion of document)
Instruction Sheet for Completing Health Care Power of Attorney/Living Will (Please discard instruction sheet after completion of document) Overview The attached Power of Attorney for Health Care form is
Top copy accepted by patient: yes/no (please ring)
Consent Form 3 Patient / Parental agreement to investigation or treatment Procedures where consciousness not impaired Name of proposed procedure or course of treatment Hospital NHS Surname no: no: OUTPATIENT
Abbvie 3D for the treatment of Hepatitis C Genotype 1
Abbvie 3D for the treatment of Hepatitis C Genotype 1 Department of Hepatology Digestive Diseases Centre Patient Information This leaflet is designed to give you important information about your new medicine.
Julie Gussenhoven, OD 3416 Bechelli Lane Redding, CA 96002
Julie Gussenhoven, OD OCULAR AND MEDICAL HISTORY QUESTIONNAIRE Name: M F Date: Date of Birth: Home Phone: Social Security #: Cell Phone: Address: Work Phone: City: Zip: Email: Please complete all personal
Trans Urethral Resection of Bladder Tumour (TURBT) (Day Case)
Trans Urethral Resection of Bladder Tumour (TURBT) (Day Case) Department of Urology Information for patients i What is a Trans Urethral Resection of Bladder Tumour (TURBT)? Your recent cystoscopy has shown
Retina Center of Oklahoma Demographic Information Sam S. Dahr,MD
Retina Center of Oklahoma Demographic Information Sam S. Dahr,MD PATIENT LAST NAME: FIRST NAME: MI: MAILING ADDRESS: CITY: STATE: ZIP CODE: HOME PHONE: WORK PHONE: CELL PHONE: MARITAL STATUS: DATE OF BIRTH:
NHS Continuing Health Care Consent Form
NHS Continuing Health Care Consent Form Surname/family name (of individual being assessed) First names Date of birth: NHS number (or other identifier)... Responsible professional 1 Name:...... Job title...
Are you at risk of blood clots?
Are you at risk of blood clots? DVT (deep vein thrombosis) & PE (pulmonary embolism) Information for patients in hospital or going home from hospital Are you at risk of blood clots? (DVT & PE) This leaflet
Advance Health Care Planning: Making Your Wishes Known. MC rev0813
Advance Health Care Planning: Making Your Wishes Known MC2107-14rev0813 What s Inside Why Health Care Planning Is Important... 2 What You Can Do... 4 Work through the advance health care planning process...
ADVANCE DIRECTIVE FOR HEALTH CARE
ADVANCE DIRECTIVE FOR HEALTH CARE This document includes a list of definitions and the two types of Advance Directives (together called a Combined Directive). Some people choose to fill out only one portion.
Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist
Policy on Pharmacological Therapies Practice Guidance Note The use of Oral Anti-Cancer Medicines and Oral Methotrexate within - V03 V03 - Issued Issue 1 Dec 15 Planned review December 2018 PPT-PGN 09 Part
COLON & RECTAL SURGERY, INC.
COLON & RECTAL SURGERY, INC. Please complete attached paperwork and bring to your appointment with your insurance card, co-pay and photo ID. If a referral is required, please be sure to contact your insurance
Bowel Screening Wales Information booklet for care homes and associated health professionals. Available in other formats on request. October.14.v.2.
Bowel Screening Wales Information booklet for care homes and associated health professionals Available in other formats on request October.14.v.2.0 Contents Section 1 Page 3 Who are Bowel Screening Wales
SMG OB/GYN Lake Lansing St. Johns Returning Patient Questionnaire (Please print clearly and Fill out Entirely)
SMG OB/GYN Lake Lansing St. Johns Returning Patient Questionnaire (Please print clearly and Fill out Entirely) Name: Former/ Maiden Name: Date of Birth: Age: Today s Date: *Language: Race: Ethnicity: *Do
Pediatric New Patient Form
Pediatric New Patient Form Internal Medicine & Pediatrics Patient Information Today's Date: Legal Name: Gender: M / F Date of Birth: Age: Race : Ethnicity: E-mail Address: Other: Home Address: Primary
Patient information. Breast Reconstruction TRAM Breast Services Directorate PIF 102 V5
Patient information Breast Reconstruction TRAM Breast Services Directorate PIF 102 V5 Your consultant has recommended that you have a TRAM flap to reconstruct your breast. TRAM stands for Transverse Rectus
PAYMENT IS REQUIRED AT THE TIME SERVICES ARE RENDERED. THANK YOU!
PATIENT INFORMATION FORM PATIENT DATA: - - PATIENT NAME (LAST, FIRST, MIDDLE) SOCIAL SECURITY # SEX ( ) - ( ) - ADDRESS HOME PHONE NUMBER MOBILE PHONE NUMBER CITY STATE ZIP CODE OCCUPATION / / DATE OF
Hickman line insertion and caring for your line
Hickman line insertion and caring for your line Information for patients This booklet explains how a Hickman line is put in, the benefits, the risks and the alternatives, as well as how to care for your
Thoracic Surgery Unit Information for Patients Having an Examination of the Lymph Glands Inside the Chest
Thoracic Surgery Unit Information for Patients Having an Examination of the Lymph Glands Inside the Chest Cervical Mediastinoscopy (often simply Mediastinoscopy ) The following information has been prepared
Advance Directive. including Power of Attorney for Health Care
Advance Directive including Power of Attorney for Health Care Overview This is a legal document, developed to meet the legal requirements for Wisconsin. This document provides a way for a person to create
Having a blue light cystoscopy
Having a blue light cystoscopy The aim of this information sheet is to help answer some of the questions you may have about having a blue light cystoscopy. It explains the benefits, risks and alternatives
Middle Initial: Street Address: City: Date of Birth: Age: Marital Status: Occupation: Employer: Name of Spouse: Emergency Contact:
SALT LAKE EYE ASSOCIATES, LLC (801) 281-2020 1025 E 3300 S, SLC, Utah * Patient Information Sheet First Name: Last Name: Middle Initial: Referred By Family Doctor EMAIL Street Address: City: State: Zip:
Covert Administration of Medicines Policy and Procedure
1 Final Draft 1. Policy Covert Administration of Medicines Policy and Procedure 1.1 Why? The Nursing and Midwifery Council has recognised there will be instances where it is appropriate to administer medication
Welcome to Pinnacle Chiropractic Spine and Sports Center
Welcome to Pinnacle Chiropractic Spine and Sports Center Name: Social Security Number: : Address: City: State: Zip: _ Telephone Home: Work: Mobile: _ Age: of Birth: Height: Weight: Gender: M / F Employer:
Laparoscopy. Women's Health Unit. Patient Information Leaflet
Laparoscopy Women's Health Unit Patient Information Leaflet February 2017 WHAT IS A LAPAROSCOPY? Laparoscopy is direct visual examination of the inside of the abdomen, using a viewing device called a laparoscope.
Welcome to Pinnacle Chiropractic Spine and Sports Center
Welcome to Pinnacle Chiropractic Spine and Sports Center Name: Social Security Number: : Address: City: State: Zip: _ Telephone Home: Work: Mobile: _ Age: of Birth: Height: Weight: Gender: M / F Employer:
Surgical Treatment for Cancer of the Oesophagus
Oxford Oesophagogastric Centre Surgical Treatment for Cancer of the Oesophagus Information for patients This leaflet gives you information about your planned operation, possible risks and complications,
Decisions about Cardiopulmonary Resuscitation (CPR)
Decisions about Cardiopulmonary Resuscitation (CPR) Information for patients and those close to them This leaflet is about Cardiopulmonary Resuscitation (CPR) and how decisions are made about it. This
Diagnostic Upper Gastrointestinal Endoscopy
Diagnostic Upper Gastrointestinal Endoscopy Endoscopy Department Patient information leaflet This leaflet explains more about having a gastroscopy, including the benefits, risks and any alternatives and
Laparoscopic Radical Nephrectomy
Urology Department Laparoscopic Radical Nephrectomy Information Aims of this leaflet To give information on the intended benefits and potential risks of kidney surgery To guide you in the decisions you
Advance Directive Form
Advance Directive Form NOTE: This form is being provided to you as a public service. The attached forms are provided as is and are not the substitute for the advice of an attorney. By providing these forms
Last Name First Middle. Mailing Address. City State Zip Phone. Date of Birth Age Soc. Sec# Cell. Employer Work Phone
Last Name First Middle Mailing Address City State Zip Phone Date of Birth Age Soc. Sec# Cell Employer Work Phone Email Address Emergency contact Phone # Relation: Name of Primary Insurance Policy # -----
Supporting Self Care Choose Pharmacy Common Ailments Service GP Practice Guide
Supporting Self Care Choose Pharmacy Common Ailments Service GP Practice Guide Contents Section 1: Introduction Section 2: Service Information Section 3: Conditions to be Treated Section 4: Referrals &
Morton s neuroma. Day Surgery Unit Patient Information Leaflet
Morton s neuroma Day Surgery Unit Patient Information Leaflet Introduction This leaflet is for patients who are considering surgery for a Morton s neuroma. It gives information on what happens during the
DURABLE HEALTH CARE POWER OF ATTORNEY AND HEALTH CARE TREATMENT INSTRUCTIONS (LIVING WILL) PART I INTRODUCTORY REMARKS ON HEALTH CARE DECISION MAKING
DURABLE HEALTH CARE POWER OF ATTORNEY AND HEALTH CARE TREATMENT INSTRUCTIONS (LIVING WILL) PART I INTRODUCTORY REMARKS ON HEALTH CARE DECISION MAKING You have the right to decide the type of health care
PATIENT INFORMATION. Address: Sex: City: State: address: Cell Phone: Home Phone: Work Phone: address: Cell Phone:
PATIENT INFORMATION Name: _ DOB: _ Age: Address: _Sex: City: _ State: _ Zip: _ Email address: Cell Phone: _ Home Phone: Work Phone: _ Responsible Party (if different from above) Name: DOB: Address: E-mail:
Deep Vein Thrombosis (DVT) - Blood Clots
Patient information Deep Vein Thrombosis (DVT) - Blood Clots i Important information for all patients. Golden Jubilee National Hospital Agamemnon Street Clydebank, G81 4DY (: 0141 951 5000 www.nhsgoldenjubilee.co.uk
Don t just go to A&E...
Greenwich Clinical Commissioning Group Don t just go to A&E... You could get quicker treatment closer to home. Don't go to A&E if it s not a serious emergency. Other NHS services are everywhere. Read this
Radical cystectomy enhanced recovery plan. Information for patients
Radical cystectomy enhanced recovery plan Information for patients Your doctor has recommended surgery to remove your bladder (radical cystectomy). This booklet is designed to explain the operation and
Upper GI Endoscopy a guide for patients and carers
Upper GI Endoscopy a guide for patients and carers Welcome to the Endoscopy Unit. This information leaflet is intended to provide you with information about an upper endoscopy. It is not expected to cover
CHPCA appreciates and thanks our funding partner GlaxoSmithKline for their unrestricted funding support for Advance Care Planning in Canada.
CHPCA appreciates and thanks our funding partner GlaxoSmithKline for their unrestricted funding support for Advance Care Planning in Canada. For more information about advance care planning, please visit
Patient & Family Guide. Blood Transfusion. Aussi disponible en français : La transfusion sanguine (FF )
Patient & Family Guide 2017 Blood Transfusion Aussi disponible en français : La transfusion sanguine (FF85-1811) www.nshealth.ca Blood Transfusion You have been given this pamphlet because you or your
Double Balloon Enteroscopy
Endoscopy Unit Double Balloon Enteroscopy A guide to the test Outpatient information Your doctor has recommended that you have a Double Balloon Enteroscopy. This leaflet will explain the procedure and
Final Choices Faithful Care
Final Choices Faithful Care A guide to important medical decisions and how to share them with those involved in your care. Mercy Health System is committed to providing care to our patients through all
INFORMATION FOR PATIENTS
The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E- mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk INFORMATION
The Home Doctor. Registration Checklist
The Home Doctor Registration Checklist All enrollees: ( ) Enrollment Form ( ) Copy of Insurance card(s) ( ) Medication List ( ) POA/Guardianship documents NOTICE Please allow two weeks for processing this
DOUGLAS JAY SPRUNG MD, FACG, FACP The Gastroenterology Group
DOUGLAS JAY SPRUNG MD, FACG, FACP The Gastroenterology Group Date: NAME: AGE: DOB: Why are you here to see the doctor today? REFERRED BY: INSURANCE HEALTH GRADES INTERNET FRIENDS/RELATIVES PCP OTHER: Medications
Endoscopy Unit. Having a Colonoscopy. A guide to the test. Outpatient information
Endoscopy Unit Having a Colonoscopy A guide to the test Outpatient information Your doctor has recommended that you have a colonoscopy. This leaflet will explain the procedure and what to expect on the
My Voice - My Choice
My Voice - My Choice My Advance Directive Table of Contents Introduction... 2 Words You Need to Know... 3 Legal Document... 4 Helpful Information about your Advance Directive... 10 What makes your life